New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China.
David Deere
Advertisement
David Deere is the chief commercialization officer for PaizaBio, a US-based contract manufacturing organization and consulting group with in-country aseptic fill-and-finish operations in Hangzhou, China. Deere is a veteran global pharmaceutical executive whose career path includes Valeant Pharmaceuticals International, F. Hoffman-La Roche and Genentech.
Articles by David Deere
Advertisement
Latest Updated Articles
Regulatory Reform in China: Implications for Global Biopharmaceutical CompaniesPublished: June 15th 2016 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharm Weekly News Roundup—Week of Oct. 13, 2025
2
Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D
3
Strategies for Building Tech Talent in the Biopharma Industry (Part 4)
4
Futureproofing Viral Safety: Global Perspectives from an Educator, Supplier, and Biosafety Expert
5
